Neos Therapeutics Reports First Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- Wells Fargo names 13 stocks as overweight tactical ideas
Neos Therapeutics (NEOS) Misses Q1 EPS by 7c, Slight Miss on Revenues
May 11, 2020 5:19 PM EDTNeos Therapeutics (NASDAQ: NEOS) reported Q1 EPS of ($0.16), $0.07 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $14.49 million versus the consensus estimate of $14.55 million.
Since late 2018, we have been steadfast in taking action to better position Neos for long-term... More
